References

1. ↵
   Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662–67

   Abstract/FREE Full Text
2. Rovaris M, Comi G, Rocca MA, et al. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 2001;124:1803–12

   Abstract/FREE Full Text
3. Weiner HL, Guttmann CR, Khoury SJ, et al. Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. J Neuroimmunol 2000;104:164–73

   CrossRefPubMedWeb of Science
4. Cotton F, Weiner HL, Jolesz FA, et al. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003;60:640–46

   Abstract/FREE Full Text
5. ↵
   Guttmann CR, Meier DS, Holland CM. Can MRI reveal phenotypes of multiple sclerosis? Magn Reson Imaging 2006;24:475–81

   CrossRefPubMed
6. ↵
   The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277–85

   Abstract/FREE Full Text
7. ↵
   Tan IL, van Schijndel RA, Fazekas F, et al. Image registration and subtraction to detect active T(2) lesions in MS: an interobserver study. J Neurol 2002;249:767–73

   CrossRefPubMedWeb of Science
8. ↵
   Warfield S, Dengler J, Zaers J, et al. Automatic identification of gray matter structures from MRI to improve the segmentation of white matter lesions. J Image Guid Surg 1995;1:326–38

   CrossRefPubMed
9. ↵
   Guttmann CR, Kikinis R, Anderson MC, et al. Quantitative follow-up of patients with multiple sclerosis using MRI: reproducibility. J Magn Reson Imaging 1999;9:509–18

   CrossRefPubMedWeb of Science
10. ↵
    Warfield SK, Kaus M, Jolesz FA, et al. Adaptive, template moderated, spatially varying statistical classification. Med Image Anal 2000;4:43–55

    CrossRefPubMedWeb of Science
11. Molyneux PD, Tofts PS, Fletcher A, et al. Precision and reliability for measurement of change in MRI lesion volume in multiple sclerosis: a comparison of two computer assisted techniques. J Neurol Neurosurg Psychiatry 1998;65:42–47

    Abstract/FREE Full Text
12. Dastidar P, Heinonen T, Vahvelainen T, et al. Computerised volumetric analysis of lesions in multiple sclerosis using new semi-automatic segmentation software. Med Biol Eng Comput 1999;37:104–07

    CrossRefPubMed
13. Alfano B, Brunetti A, Larobina M, et al. Automated segmentation and measurement of global white matter lesion volume in patients with multiple sclerosis. J Magn Reson Imaging 2000;12:799–807

    CrossRefPubMedWeb of Science
14. Ashton EA, Takahashi C, Berg MJ, et al. Accuracy and reproducibility of manual and semiautomated quantification of MS lesions by MRI. J Magn Reson Imaging 2003;17:300–08

    CrossRefPubMedWeb of Science
15. Anbeek P, Vincken KL, van Osch MJ, et al. Automatic segmentation of different-sized white matter lesions by voxel probability estimation. Med Image Anal 2004;8:205–15

    CrossRefPubMed
16. Anbeek P, Vincken KL, van Osch MJ, et al. Probabilistic segmentation of white matter lesions in MR imaging. Neuroimage 2004;21:1037–44

    CrossRefPubMed
17. ↵
    Duan Y, Moscufo N, Pouwels PJ, et al. Synergies of high-resolution multi-channel lesion segmentation in multiple sclerosis: MPRAGE, 3D FLAIR, 3D T2WI and 3D DIR. In: ISMRM. May2006 , Seattle; ISMRM:2006:3116
18. ↵
    Tan IL, van Schijndel RA, Pouwels PJ, et al. Serial isotropic three-dimensional fast FLAIR imaging: using image registration and subtraction to reveal active multiple sclerosis lesions. AJR Am J Roentgenol 2002;179:777–82

    PubMedWeb of Science
19. ↵
    Wei X, Warfield SK, Zou KH, et al. Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy. J Magn Reson Imaging 2002;15:203–09

    CrossRefPubMedWeb of Science
20. ↵
    Hohol MJ, Guttmann CR, Orav J, et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol 1997;54:1018–25

    CrossRefPubMedWeb of Science
21. ↵
    Friston KJ, Ashburner J, Frith C, et al. Spatial registration and normalization of images. Hum Brain Mapp 1995;2:165–89
22. ↵
    Kiebel SJ, Ashburner J, Poline JB, et al. MRI and PET coregistration–a cross validation of statistical parametric mapping and automated image registration. Neuroimage 1997;5:271–79

    CrossRefPubMed
23. ↵
    Meier DS, Guttmann CR. Time-series analysis of MRI intensity patterns in multiple sclerosis. Neuroimage 2003;20:1193–209

    CrossRefPubMed
24. ↵
    Altman DG, Bland JM. Comparison of methods of measuring blood pressure. J Epidemiol Community Health 1986;40:274–77

    FREE Full Text
25. ↵
    Lee MA, Smith S, Palace J, et al. Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging. Brain 1998;121:2095–102

    Abstract/FREE Full Text
26. ↵
    Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993;116:1077–94

    Abstract/FREE Full Text
27. ↵
    Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002;59:1412–20

    Abstract/FREE Full Text
28. ↵
    Guttmann C, Warfield S, Guimond A, et al. Variability of brain atrophy estimates in multiple sclerosis. Proc Intl Soc Mag Reson Med 2000;1188
29. ↵
    Molyneux PD, Miller DH, Filippi M, et al. The use of magnetic resonance imaging in multiple sclerosis treatment trials: power calculations for annual lesion load measurement. J Neurol 2000;247:34–40

    CrossRefPubMedWeb of Science
30. ↵
    PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498–504

    CrossRefPubMedWeb of Science
31. ↵
    Gawne-Cain ML, Webb S, Tofts P, et al. Lesion volume measurement in multiple sclerosis: how important is accurate repositioning? J Magn Reson Imaging 1996;6:705–13

    PubMedWeb of Science
32. ↵
    Rovaris M, Gawne-Cain ML, Sormani MP, et al. The effect of repositioning on brain MRI lesion load assessment in multiple sclerosis: reliability of subjective quality criteria. J Neurol 1998;245:273–75

    CrossRefPubMed
33. ↵
    Meier DS, Weiner HL, Guttmann CR. Time-series modeling of MS disease activity: a promising window on disease progression and repair potential. Neurotherapeutics 2007;4:485–98

    CrossRefPubMed
34. ↵
    Rudick RA, Fisher E, Lee JC, et al. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler 2000;6:365–72

    Abstract/FREE Full Text
35. ↵
    Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128:2705–12

    Abstract/FREE Full Text
36. ↵
    Wattjes MP, Lutterbey GG, Gieseke J, et al. Double inversion recovery brain imaging at 3T: diagnostic value in the detection of multiple sclerosis lesions. AJNR Am J Neuroradiol 2007;28:54–59

    Abstract/FREE Full Text
37. Mugler JP 3rd, Bao S, Mulkern RV, et al. Optimized single-slab three-dimensional spin-echo MR imaging of the brain. Radiology 2000;216:891–99

    CrossRefPubMedWeb of Science
38. Pouwels PJ, Kuijer JP, Mugler JP 3rd, et al. Human gray matter: feasibility of single-slab 3D double inversion-recovery high-spatial-resolution MR imaging. Radiology 2006;241:873–79

    CrossRefPubMedWeb of Science
39. ↵
    Geurts JJ, Pouwels PJ, Uitdehaag BM, et al. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 2005;236:254–60

    CrossRefPubMedWeb of Science